Sun, Ranbaxy Q2 in line with expectations; stocks expensive: Nirmal Bang
PUBLISHED ON: November 9, 2012 | Duration: 5 min, 01 sec
Praful Bohra, senior research analyst – pharmaceuticals at Nirmal Bang Institutional Equities, speaks to NDTV about the valuations of pharma stocks and Q2 earnings announcement by Sun Pharma and Ranbaxy.
